title: Amelioration of white-matter lesions in a patient with Fabry disease.
abstract: We report on a 27-year-old man with Fabry disease who had widespread white-matter lesions (WMLs) despite the absence of renal or cardiac manifestations. Genomic analysis revealed a novel mutation: a GAT deletion at nucleotide position 234-236 in exon 5 of the coding region. After 12 months of enzyme replacement therapy (ERT), most of the WMLs had disappeared. Cell counts and protein levels in the cerebrospinal fluid also decreased. These findings suggest that ERT may play a role in the recovery of WMLs.
authors.affiliation: Department of Neurology D4, Osaka University Graduate School of Medicine, Osaka, Japan. misaky@neurol.med.osaka-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Yamadera
authors.forename: M
authors.initials: M
authors.lastname: Yokoe
authors.forename: G
authors.initials: G
authors.lastname: Beck
authors.forename: M
authors.initials: M
authors.lastname: Mihara
authors.forename: H
authors.initials: H
authors.lastname: Oe
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: S
authors.initials: S
authors.lastname: Sakoda
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D000795:Fabry Disease / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009413:Nerve Fibers, Myelinated / Q000187:drug effects* / Q000473:pathology; D017384:Sequence Deletion; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D000519:alpha-Galactosidase